• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向MEK1/2激酶的变构抑制剂对Ser222磷酸化抑制机制的分子动力学模拟

Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase.

作者信息

Mudedla Sathish K, Lee Hayoung, Kim Jeom Ji, Jang Seong Hun, Doddareddy Munikumar R, Sanam Swetha Y, Gundabathula Rochish, Park Jang-June, Wu Sangwook

机构信息

PharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.

Drug Discovery Division, ISU Abxis, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea.

出版信息

ACS Omega. 2024 Jul 10;9(29):31946-31956. doi: 10.1021/acsomega.4c03615. eCollection 2024 Jul 23.

DOI:10.1021/acsomega.4c03615
PMID:39072081
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11270731/
Abstract

Allosteric inhibitors of mitogen-activated protein kinase 1 (MEK1) reveal distinct interactions with MEK1 activation loop residues. The structural analyses will determine whether, and how, distinct inhibitors suppress the phosphorylation of MEK1 and may guide future therapeutic development. In this study, we explored the suppression mechanism of the phosphorylation process in the presence of MEK allosteric inhibitors, such as selumetinib, trametinib, cobimetinib, and CH5126766, by employing molecular dynamics simulations accompanied by principal component analysis. The simulations of wildtype MEK1 show that Ser222 can come close to γ-phosphate but not Ser218. We have found the conformation where Ser222 is within 5 Å of distance, which makes Ser222 accessible for γ-phosphate. The conformation analysis from the simulations of MEK1 in the presence of allosteric inhibitors reveals that the inhibitor restricts the flexibility of Ser222 through strong interactions with the activation loop, Lys97, and water mediates interactions with amino acids in the vicinity. The results reveal that all the inhibitors act as screeners between the activation loop and Mg-ATP and restricting the flexibility of the activation loop through strong interaction causes the suppression of the phosphorylation process of MEK1. The results conclude that a strong interaction of allosteric inhibitors with the activation loop restricts the movement of Ser222 toward Mg-ATP, which could be the dominant factor for the suppression of phosphorylation in MEK1. This research will provide novel insights to design effective anticancer therapeutics for targeting MEK1 in the future.

摘要

丝裂原活化蛋白激酶1(MEK1)的变构抑制剂与MEK1激活环残基表现出不同的相互作用。结构分析将确定不同的抑制剂是否以及如何抑制MEK1的磷酸化,并可能指导未来的治疗发展。在本研究中,我们通过分子动力学模拟并结合主成分分析,探索了在存在MEK变构抑制剂(如司美替尼、曲美替尼、考比替尼和CH5126766)的情况下磷酸化过程的抑制机制。野生型MEK1的模拟结果表明,Ser222可以接近γ-磷酸,但Ser218不行。我们发现了Ser222距离在5 Å以内的构象,这使得Ser222可接近γ-磷酸。在变构抑制剂存在下对MEK1进行模拟的构象分析表明,抑制剂通过与激活环、Lys97的强相互作用限制了Ser222的灵活性,并且水介导了与附近氨基酸的相互作用。结果表明,所有抑制剂都充当激活环和Mg-ATP之间的筛选器,通过强相互作用限制激活环的灵活性会导致MEK1磷酸化过程的抑制。结果得出结论,变构抑制剂与激活环的强相互作用限制了Ser222向Mg-ATP的移动,这可能是抑制MEK1磷酸化的主要因素。这项研究将为未来设计针对MEK1的有效抗癌疗法提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/d9efeba3afee/ao4c03615_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/1797d283d1b6/ao4c03615_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/9d8b4c1b47fd/ao4c03615_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/b65337ee5365/ao4c03615_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/fb51cbbf0528/ao4c03615_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/2ef1a02e7e27/ao4c03615_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/35cf0b2ff65e/ao4c03615_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/7b969e116f58/ao4c03615_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/5f69e38de5ec/ao4c03615_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/8262a98270e1/ao4c03615_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/4dc4524033e3/ao4c03615_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/bb36b7c181b0/ao4c03615_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/d9efeba3afee/ao4c03615_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/1797d283d1b6/ao4c03615_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/9d8b4c1b47fd/ao4c03615_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/b65337ee5365/ao4c03615_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/fb51cbbf0528/ao4c03615_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/2ef1a02e7e27/ao4c03615_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/35cf0b2ff65e/ao4c03615_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/7b969e116f58/ao4c03615_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/5f69e38de5ec/ao4c03615_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/8262a98270e1/ao4c03615_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/4dc4524033e3/ao4c03615_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/bb36b7c181b0/ao4c03615_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8410/11270731/d9efeba3afee/ao4c03615_0012.jpg

相似文献

1
Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase.靶向MEK1/2激酶的变构抑制剂对Ser222磷酸化抑制机制的分子动力学模拟
ACS Omega. 2024 Jul 10;9(29):31946-31956. doi: 10.1021/acsomega.4c03615. eCollection 2024 Jul 23.
2
Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.变构激酶抑制剂重塑细胞内和计算机模拟中的MEK1激酶活性构象。
Biomolecules. 2021 Mar 30;11(4):518. doi: 10.3390/biom11040518.
3
Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation.MEK1/2 与曲美替尼相互作用的分子机制研究:对接和分子动力学模拟。
Interdiscip Sci. 2019 Mar;11(1):115-124. doi: 10.1007/s12539-018-0305-4. Epub 2018 Nov 21.
4
The mechanism of activation of MEK1 by B-Raf and KSR1.B-Raf 和 KSR1 激活 MEK1 的机制。
Cell Mol Life Sci. 2022 May 4;79(5):281. doi: 10.1007/s00018-022-04296-0.
5
Mechanism of Abnormal Activation of MEK1 Induced by Dehydroalanine Modification.脱羟丙氨酸修饰诱导 MEK1 异常激活的机制。
Int J Mol Sci. 2024 Jul 8;25(13):7482. doi: 10.3390/ijms25137482.
6
Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib.基于计算机的研究:失活/激活突变对曲美替尼抑制 MEK1 的影响。
Int J Mol Sci. 2020 Mar 21;21(6):2167. doi: 10.3390/ijms21062167.
7
Computational targeting of allosteric site of MEK1 by quinoline-based molecules.基于喹啉的分子对 MEK1 变构位点的计算靶向。
Cell Biochem Funct. 2022 Jul;40(5):481-490. doi: 10.1002/cbf.3709. Epub 2022 May 23.
8
Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.包括考比替尼和曲美替尼在内的变构MEK1/2抑制剂在皮肤黑色素瘤治疗中的应用。
Pharmacol Res. 2017 Mar;117:20-31. doi: 10.1016/j.phrs.2016.12.009. Epub 2016 Dec 9.
9
MEK1/2 inhibitors in the treatment of gynecologic malignancies.MEK1/2 抑制剂在妇科恶性肿瘤治疗中的应用。
Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14.
10
Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.新型高亲水性非 ATP 竞争性 MEK1/2 抑制剂 SMK-17 的抗肿瘤作用。
Anticancer Drugs. 2012 Jan;23(1):119-30. doi: 10.1097/CAD.0b013e32834c6a33.

引用本文的文献

1
Decoding allosteric landscapes: computational methodologies for enzyme modulation and drug discovery.解读变构景观:用于酶调节和药物发现的计算方法
RSC Chem Biol. 2025 Feb 14;6(4):539-554. doi: 10.1039/d4cb00282b. eCollection 2025 Apr 2.

本文引用的文献

1
Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.疾病相关 MEK 突变体的定性差异揭示了癌症中的分子特征和异常信号串扰。
Nat Commun. 2022 Jul 13;13(1):4063. doi: 10.1038/s41467-022-31690-w.
2
AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models.AlphaFold 蛋白质结构数据库:用高精度模型极大地扩展蛋白质序列空间的结构覆盖范围。
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444. doi: 10.1093/nar/gkab1061.
3
Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation.
变构 MEK 抑制剂作用于 BRAF/MEK 复合物以阻断 MEK 的激活。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2107207118.
4
Best Practices for Alchemical Free Energy Calculations [Article v1.0].炼金术自由能计算的最佳实践 [文章v1.0]
Living J Comput Mol Sci. 2020;2(1). doi: 10.33011/livecoms.2.1.18378.
5
AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings.AutoDock Vina 1.2.0:新的对接方法、扩展的力场及Python绑定
J Chem Inf Model. 2021 Aug 23;61(8):3891-3898. doi: 10.1021/acs.jcim.1c00203. Epub 2021 Jul 19.
6
Highly accurate protein structure prediction with AlphaFold.利用 AlphaFold 进行高精度蛋白质结构预测。
Nature. 2021 Aug;596(7873):583-589. doi: 10.1038/s41586-021-03819-2. Epub 2021 Jul 15.
7
Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.MEK1/2 抑制剂和降解剂在癌症治疗中的研究进展。
Eur J Med Chem. 2021 Jun 5;218:113386. doi: 10.1016/j.ejmech.2021.113386. Epub 2021 Mar 19.
8
MEK inhibitors for the treatment of non-small cell lung cancer.MEK 抑制剂治疗非小细胞肺癌。
J Hematol Oncol. 2021 Jan 5;14(1):1. doi: 10.1186/s13045-020-01025-7.
9
How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study.致癌突变如何激活人类 MAP 激酶 1(MEK1):分子动力学模拟研究。
J Biomol Struct Dyn. 2020 Aug;38(13):3942-3958. doi: 10.1080/07391102.2019.1686065. Epub 2019 Nov 6.
10
Current Development Status of MEK Inhibitors.MEK 抑制剂的当前发展状况。
Molecules. 2017 Sep 26;22(10):1551. doi: 10.3390/molecules22101551.